Maria Giovanna Eva Papadopoulos

Dr. Maria Giovanna Eva Papadopoulos

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
DADomenico Alberga
Domenico Alberga
VNVittoria Nanna
Vittoria Nanna
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
AAAdolfo Ancona
Adolfo Ancona
MLMaria Cristina Lomuscio
Maria Cristina Lomuscio
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Achieving optimal target activity while maintaining synthetic accessibility and drug-likeness represents a major challenge in computational drug discovery. Existing de novo generative models often yield chemically invalid or synthetically intractable structures and struggle to optimize multiple objectives simultaneously. Here, we introduce ALCHIMIA, an interpretable hybrid framework combining reinforcement learning (RL) and a genetic algorithm (GA), built based on a vocabulary of 33 medicinal chemistry-inspired molecular transformations. The RL component trains a policy network to prioritize transformation sequences that improve synthetic accessibility (SA) and the quantitative estimate of drug-likeness (QED) scores, embedding these constraints directly into molecular generation. The GA component applies the learned policy as a mutational operator within population-based optimization guided by molecular docking, enabling the exploration of diverse chemical lineages while converging toward high-affinity ligands. ALCHIMIA was applied to two different pharmacologically relevant targets: human Cannabinoid Receptor 2 (CB2R) and human Sigma nonopioid intracellular Receptor 1 (S1R). We considered three different scenarios: (i) unconstrained hit identification; (ii) scaffold-constrained lead optimization; and (iii) design of dual modulators. The framework generated chemically valid molecules with QED and SA scores comparable to or better than those obtained with random baselines and selected de novo design methods. By codifying typical medicinal chemistry actions as learnable transformations and coupling multiobjective optimization with GA-based diversity maintenance, ALCHIMIA, freely available as a GitHub repository (https://github.com/alberdom88/ALCHIMIA), provides a practical, interpretable, and scalable framework for molecular de novo design.

5 July 2025 in Crystals
Verified
Journal Article
Open access
PDF file
GLGianfranco Lopopolo
Gianfranco Lopopolo
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
CCCorrado Cuocci
Corrado Cuocci
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Antonio LopalcoAntonio Lopalco
Antonio Lopalco
RRRosanna Rizzi
Rosanna Rizzi
This study reports the discovery and structural characterization of a novel polymorph, designated as Form III, of Alclometasone dipropionate, a corticosteroid commonly used in the treatment of inflammatory dermatoses. Form III was obtained by modifying the crystallization conditions reported in prior art and was thoroughly characterized using Powder X-ray Diffraction (PXRD), Fourier Transform Infrared (FT-IR) spectroscopy, melting-point determination, Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), including its first derivative (DTG), optical microscopy, and Scanning Electron Microscopy (SEM). In parallel, pure Form II, previously observed only in mixtures with Form I, was successfully isolated and characterized using the same analytical techniques. Both forms were compared in terms of structural, thermal, and morphological properties. PXRD analysis revealed that Form III crystallizes in a triclinic system; FT-IR spectroscopy revealed unique vibrational signatures, and microscopy showed rod-like crystal morphology. The discovery of Form III expands the current understanding of the solid-state landscape of Alclometasone dipropionate and opens opportunities for the identification of new industrial purification methods for the compound.

11 October 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
GBGiuseppe Bonapace
Giuseppe Bonapace
LTLorenzo Taglietti
Lorenzo Taglietti
Barbara La FerlaBarbara La Ferla
Barbara La Ferla
Rosanna RizziRosanna Rizzi
Rosanna Rizzi
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi
Mucopolysaccharidosis Type I (MPS I) is a rare autosomal recessive lysosomal storage disorder caused by mutations in α‐ʟ‐iduronidase (IDUA) enzyme, a glycosylated hydrolase responsible for glycosaminoglycan (GAG) degradation. Pathogenic variants are associated with a broad clinical spectrum, from severe Hurler syndrome to attenuated Scheie phenotype. The missense mutations L490P and P533R cause attenuated‐intermediate MPS I, retaining residual enzyme activity. To investigate the structural mechanisms underlying these phenotypes, we performed all‐atom molecular dynamics simulations –18 trajectories of 1.6 μs each– comparing wild type IDUA with L490P and P533R mutants at pH 7.5 and 4.5, mimicking the endoplasmic reticulum (ER) and lysosomal microenvironments, respectively. Backbone root‐mean‐square deviation and fluctuation analyses indicated that the overall protein fold was maintained across conditions; however, we identified a pH‐dependent restricted conformational flexibility of the N372‐linked glycan in both mutants. Cluster analysis performed on the obtained trajectories showed that both mutations affect the conformation of this glycan. Hydrogen bond analysis further revealed that P533R induces aberrant, persistent glycan–protein interactions, providing a possible structural explanation for reduced IDUA activity and, therefore, GAG processing. Our findings, supported by in vitro data, propose glycan conformational restriction as a possible new molecular mechanism that underpins enzymatic dysfunction in attenuated MPS I, opening new avenues for structure‐informed therapeutic strategies.

7 October 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Giovanni GrazianoGiovanni Graziano
Giovanni Graziano
FMFrancesco Mastropasqua
Francesco Mastropasqua
AFAnnalisa Fanizzi
Annalisa Fanizzi
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
ALAntonio Laghezza
Antonio Laghezza
Marialessandra ContinoMarialessandra Contino
Marialessandra Contino

10 January 2026
Verified
Book Chapter
Closed access
PDF file
MLMaria Cristina Lomuscio
Maria Cristina Lomuscio
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
MCMiriana Calvano
Miriana Calvano
VNVittoria Nanna
Vittoria Nanna
ACAntonio Curci
Antonio Curci
GMGiuseppe Felice Mangiatordi
Giuseppe Felice Mangiatordi

16 October 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
IMIvan Mercurio
Ivan Mercurio
FCFederica Carucci
Federica Carucci
VNVittoria Nanna
Vittoria Nanna
SMSara Di Marino
Sara Di Marino
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
DADomenico Alberga
Domenico Alberga
Phosphoprotein Enriched in Diabetes/Astrocytes 15 (PED/PEA-15) is a 15 kDa adaptor protein whose overexpression drives tumorigenesis and type II diabetes through dysregulated protein-protein interactions (PPIs) mediated by its Death Effector Domain (DED). Despite its therapeutic relevance, no potent small-molecule inhibitors targeting the DED have yet been identified. Here, we employed a fragment-based drug discovery approach combining 19F and 1H NMR screening of a 118-compound fluorinated library to identify F2 a fragment that binds the PED/PEA-15 DED with an estimated dissociation constant of 150 μM. NMR chemical shift perturbation analysis mapped the binding site to the α2-α3 loop, α3, and α5 helices. To better characterise the protein, Small-angle X-ray scattering of the apo protein was employed, yielding a structural model in which the C-terminal tail is consistent with a conformation that is not maximally extended. Induced fit docking and molecular dynamics simulations of the PED/PEA-15-F2 complex supported a plausible binding pose and suggested a ligand-induced destabilisation of the α3 helix propagating to the α6 helix. Correlation network analysis further suggests a hypothesis in which F2 rewires the dynamic architecture of the DED and alters allosteric communication between residues of the DED and the C-terminal tail. The identification of a ligand-accessible site on the DED supports the druggability of PED/PEA-15 and provides a refined structural framework for fragment optimisation and for testing whether engagement of this site can be translated into modulation of PED/PEA-15 PPIs with therapeutic potential in cancer and type II diabetes.